Cetera Investment Advisers
KYMR icon

Cetera Investment Advisers’s Kymera Therapeutics KYMR Stock Holding History

Cetera Investment Advisers’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$300K Buy
3,602
+252
+8% +$20K ﹤0.01% 3984
2025
Q4 		$261K Buy
+3,350
New +$226K ﹤0.01% 4027

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Cetera Investment Advisers's KYMR Position: Q1 2026 in Review

Cetera Investment Advisers increased its Kymera Therapeutics (KYMR) stake by 7.5% in Q1 2026, buying an estimated $20K and bringing the position to 3,602 shares worth $300K. The position accounts for ﹤0.01% of the portfolio, ranked #3984.

Cetera Investment Advisers first reported a position in KYMR in Q4 2025 and has held it in 2 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Cetera Investment Advisers held 3,602 shares of Kymera Therapeutics worth $300K as of Q1 2026.
  • Cetera Investment Advisers bought 252 Kymera Therapeutics shares in Q1 2026, an estimated $20K.
  • Kymera Therapeutics made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #3984 holding.
  • Cetera Investment Advisers first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.